Tuesday 12 February 2013

Selumetinib in patients with recurrent low-grade serous carcinoma of the ovary or peritoneum

Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails. After surgery, with or without pre-surgical chemotherapy, when low-grade serous ovarian cancer persists or returns, chemotherapy and hormonal therapy are relatively ineffective, according to Dr David Gershenson, professor in the University of Texas MD Anderson Cancer Center Department of Gynecological Oncology and Reproductive Medicine. Read more here.

Study mentioned: Farley J, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb;14(2):134-40. Epub 2012 Dec 21. PMID: 23261356

No comments:

Post a Comment